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Abstract
Background: Toward the goals of providing an additional vector to add to the armamentarium
available to HIV vaccinologists and of creating a bivalent vaccine effective against dengue virus and
HIV, we have attempted to create vectors which express dengue virus non-structural proteins and
HIV immunogens. Previously we reported the successful construction of dengue virus replicons
which lack structural genes necessary for virion release and spreading infection in culture but which
can replicate intracellularly and abundantly produce dengue non-structural proteins. Here we
attempted to express heterologous genetic material from these replicons.
Results: We cloned into a ∆ pre-M/E dengue virus replicon genes for either green fluorescent
protein (GFP), HIV gp160 or HIV gp120 and tested the ability of these constructs to express
dengue virus proteins as well as the heterologous proteins in tissue culture after transfection of
replicon RNA.
Conclusions: Heterologous proteins were readily expressed from these constructs. GFP and
gp120 demonstrated minimal or no toxicity. Gp160 expressing replicons were found to express
proteins abundantly at 36 hours post transfection, but after 50 hrs of transfection, few replicon
positive cells could be found despite the presence of cellular debris positive for replicon proteins.
This suggested that gp160 expressed from dengue virus replicons is considerably more toxic than
either GFP or gp120. The successful expression of heterologous proteins, including HIV gp120 for
long periods in culture suggests this vector system may be useful as a vaccine vector, given
appropriate delivery methods.
Background
Despite tremendous progress in developing anti-retrovi-
ral drugs to combat HIV, there remains a need for an ef-
fective HIV vaccine. This need is particularly pressing in
third world countries, where demographics and econom-
ics make drug therapy difficult to deliver. Although HIV
infection elicits neutralizing antibodies and a cellular im-
mune response against the virus [reviewed in [1] & [2]]
and there exist "exposed uninfected" (EU) individuals
that appear to have acquired resistance to infection by
HIV [3,4], the hallmark of HIV infection is the almost
universal inability of humans to mount an immune re-
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sponse that can prevent the eventual development of
AIDS.
An effective vaccine will require not only the design of ef-
fective immunogens, but also the design of optimized
protocols of immunogen delivery. As a live, attenuated
vaccine for HIV is considered difficult to test and danger-
ous to implement [1,2,5–9], various alternatives to HIV
could be considered as potential "live" vectors for HIV
immunogens, including enteric bacteria, poxviruses
(vaccinia and canarypox), small RNA viruses (e.g. polio-
virus and Semliki Forest virus), Rhabdoviruses (e.g. ve-
sicular stomatitis virus), DNA viruses (e.g. adenovirus
and adeno-associated viruses) and even naked DNA to
achieve expression in living host cells [2,10].
Dengue possesses several advantages which favor its
choice as a vector for HIV immunogens. As a flavivirus,
it replicates entirely in the cytoplasm through RNA di-
rected RNA polymerization and is incapable of integrat-
ing into the host genome. Flavivirus replicons can
replicate inside cells and achieve prolonged expression
of high levels of virally encoded proteins with minimal
toxicity [11,12] and are unable to recombine or mutate to
produce infectious HIV particles. Finally, by eliciting an
immune reaction against the dengue non-structural pro-
teins remaining in replicons, dengue virus replicons may
induce a protective immunity against dengue which
would not predispose vaccinated individuals to DHF.
Properly administered, dengue virus replicons express-
ing HIV epitopes might thus serve as dual vaccines, con-
ferring protection against dengue virus as well as HIV.
The challenges in developing a safe and effective HIV
vaccine are many and varied. Choice of immunogen is
clearly problematic. Critical epitopes may be masked by
glycosyl groups and/or tertiary structure [13–15] and
[16] The extensive genetic variability of HIV complicates
immunogen choice and the high rate of mutation in-
creases the likelihood of the rapid development of resist-
ance. Furthermore, the method of immunogen delivery
(e.g. purified subunits or inactivated virus vs. various
forms of "live" expression) can determine the relative na-
ture and extent of humoral and cell mediated immuno-
logic responses. Priming with various types of "live"
expression followed by boosting with purified subunits is
currently favored as a method to obtain stronger immu-
nologic responses that either method alone [reviewed in
[1] and [2]]. Previously acquired immunity to a viral vec-
tor such as vaccinia may influence its efficacy in inducing
immunity against heterologous proteins being delivered
[16–19] and it may be wise to provide physicians with
HIV vaccines based on a variety of vectors to handle a va-
riety of clinical situations.
The use of live dengue as a vaccine or as a vector for het-
erologous immunogens has historically been considered
problematic because of the pathologies associated with
dengue infection. Although dengue fever (DF) is usually
self limited, dengue hemorrhagic fever (DHF) is consid-
erably debilitating and frequently fatal [20]. However,
DHF is unlikely to result from or be promoted by the vec-
tors reported here. The enhanced replication of virus
seen in dengue hemorrhagic fever is generally seen upon
reinfection by dengue virus of a serotype different from
previous infections and is believed to be mediated by an-
tibodies against viral structural proteins: so called anti-
body dependent enhancement of infection, or ADE.
These cross reacting antibodies actually promote viral
uptake by macrophages [21,22]. The main challenge in
using live dengue in humans is thus avoiding the devel-
opment of antibody dependent enhancement(ADE) of
infection by antibodies against the pre-M and E proteins
of one dengue strain which weakly cross react with the
pre-M and E of a second infecting dengue strain. Since
the replicons reported here lack the major viral structur-
al protein genes, they are not only incapable of sustain-
ing a spreading infection but also are incapable of
eliciting antibodies against the missing structural pro-
teins. They should neither induce DF nor promote DHF.
Dengue virus has a typical flavivirus genome structure,
as described in Figure 1. The structural proteins, C, pre-
M (M) and E, are involved in packaging, export and sub-
sequent entry. The non-structural proteins, NS1, NS2A,
NS2B, NS3, NS4A, NS4B and NS5 include an RNA-di-
rected RNA polymerase and a protease function involved
in cleaving certain positions of the long viral polyprotein
which contains all the viral genes [23,24]. The four sero-
types of dengue virus ("1" through "4") share approxi-
mately 60%-74% amino acid residue identity with one
another in the E gene [25] and induce cross-reacting an-
tibodies [26].
Two strategies suggest themselves for circumventing the
problem of ADE from dengue vaccination. One strategy
is to immunize with multiple strains of dengue virus to
elicit high affinity, neutralizing antibodies against the
multiple dengue serotypes. At least one vaccine to do this
(using dengue vaccine candidates, DEN-1 PDK13, DEN-
2 PDK53, DEN-3 PGMK 30/F3, and DEN-4 PDK48) has
been in clinical trials [27,28]. A second strategy is to in-
duce immunity only to viral proteins other than pre-M
and E. Several studies have shown that the nonstructural
glycoprotein NS1 can play an important role in protec-
tion against dengue. Mice immunized with purified den-
gue-2 NS1 protein injected intramuscularly and boosted
after 3 days and two weeks were protected from develop-
ing lethal dengue encephalitis upon subsequent chal-
lenge with dengue 2 virus. [29]. Similarly, miceBMC Microbiology 2001, 1:28 http://www.biomedcentral.com/1471-2180/1/28
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Figure 1
Construction of wild type dengue virus and dengue virus replicon vectors used in these studies. The diagram at the top repre-
sents the wild type dengue virus genome.
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immunized with recombinant vaccinia virus expressing
authentic NS1 [30] were protected against the develop-
ment of dengue-4 virus encephalitis when challenged by
intracerebral injection. Inoculation of mice with specific
combinations of monoclonal antibodies (Mabs) directed
against dengue-2 NS1 [31] also protects against lethal vi-
rus encephalitis upon intracerebral dengue-2 challenge.
Other nonstructural proteins are also immunogenic and
may participate in eliciting protection [32].
Previously we have reported the successful construction
of several dengue virus replicons which replicate intrac-
ellularly without the pre-M and E proteins required to
form infectious virions, including one replicon which can
be expressed from transfected DNA [12]. Towards the
goal of devising a "live" dual vaccine based on only non-
structural dengue proteins and heterologous HIV mate-
rial, we report here that these replicons can be harnessed
to express heterologous genes, including HIV gp160 and
gp120. Upon introduction into a host's cells, these sub-
genomic fragments should replicate intracellularly and
support prolonged expression of dengue and heterolo-
gous immunogens without producing the deleted dengue
structural proteins and without forming infectious viri-
ons.
Results
In various previous attempts to express heterologous
genes in full length, wild type dengue virus, we experi-
enced a very poor success rate, despite attempts to clone
heterologous material into various positions of the ge-
nome (data not shown). Our first efforts to determine
whether or not heterologous material could be readily
expressed in dengue replicons was to clone the compar-
atively tractable green fluorescent protein (GFP) into the
∆ pre-M/E replicon, into the position from which the pre-
M and E genes had been deleted (Figure 1). GFP was
readily visualized in cultures 48 hours post transfection
with ∆ pre-M/E-GFP, as seen in Figure 2.
Encouraged by the success with GFP, we next looked at
∆ pre-M/E replicons with HIV-1 env material cloned into
the position of the deleted pre-M and E genes. We ana-
lyzed two clones, ∆ pre-M/E-gp120 and ∆ pre-M/E-
gp160, expressing HIV-1 gp120 and gp160 respectively
(Figure 1). Expression of genes in the ∆ pre-M/E-gp120
replicon was reproducibly visualized at 48–50 hours
post transfection (Figures 3 & 4), at a level of approxi-
matley 1% of the cells, but in many experiments, the cor-
responding cultures transfected with the gp160 replicon,
∆ pre-M/E-gp160, either no fluorescence could be visual-
ized (not shown), or only fluorescent cells with a bizarre
morphology (characterized by debris and/or degenera-
tive appearance) could be visualized (Figure 5). Howev-
er, when we harvested cultures earlier, at 36 hours post
transfection with ∆ pre-M/E-gp160, intact, fluorescing
cells were readily found, though the morphology still ap-
peared atypical compared to either that of cultures trans-
fected with wild type dengue virus and dengue replicons
[12] or the ∆ pre-M/E-gp120 replicon (see Figure 6).
To serve as effective vaccines, it is preferable, if not nec-
essary, that expression systems be capable of expressing
immunogens for longer than a couple of days. Although
we knew from previous experiments [12] that dengue
replicons could survive for at least 7 days in culture, the
limited durability of cells transfected with gp160-ex-
pressing replicons raised the question of whether or not
cells transfected with ∆ pre-M/E-gp120 replicons could
survive for similarly long times in culture. When cultures
transfected with ∆ pre-M/E-gp120 were trypsinized and
replated on day 7 post transfection and then analyzed on
day 9 post transfection, fluorescent cells were readily vis-
ualized (Figure 7). In comparison to cultures that were
not trypsinized on day 7 post transfection however, these
Figure 2
Expression of green fluorescent protein (GFP) by ∆ pre-M/E-
GFP 48 hours post transfection.
Figure 3
Expression of proteins by ∆ pre-M/E-gp120 50 hours post
transfection. Left and right frames are two independent
fields. Anti-dengue serum was used in these experiments.BMC Microbiology 2001, 1:28 http://www.biomedcentral.com/1471-2180/1/28
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cultures had fewer intact fluorescent cells and more de-
bris (not shown). Although this suggests that gp120 ex-
pression from a dengue replicon stresses cells, we did
find fields with adjacent, gp120 positive cells, suggesting
that at least one cell division between day 7 and day 9 had
occurred in a cell successfully transfected with ∆ pre-M/
E-gp120 (Figure 7, right panel). A 9 days of culture post
transfection with ∆ pre-M/E-gp120, only about 0.1% of
the cells or less were positive (not shown), which repre-
sents a considerable decrease from 48 hours post trans-
fection.
In the experiments described above and in Figures 3
through 7, expression of dengue replicons with heterolo-
gous material from HIV was followed either using anti-
HIV sera or anti-dengue sera, depending on the experi-
ment. To demonstrate that the same cells were express-
ing both dengue proteins and HIV proteins, we used a
double label technique, with FITC detecting HIV pro-
teins and rhodamine detecting dengue proteins. Figure 8
demonstrates the concordance of dengue virus protein
and gp120 expression in cultures 4 days post transfection
with ∆ pre-M/E-gp120, (Figure 8). The more extensive
background of auto fluorescence encountered when vis-
ualizing the rhodamine fluorescence makes low levels of
specific rhodamine fluorescence more difficult to dis-
cern, but clearly all intact cells positive for HIV are also
positive for dengue proteins. The rhodamine-positive
spot in the lower left of the panel is cellular debris and is
also positive for dengue proteins, but the FITC fluores-
cence was not well reproduced by digital photography,
though it still may be visualized on certain monitor/com-
puter combinations. Similar results were obtained at 7
days post transfection (Figure 9).
Discussion
Our finding that dengue virus replicons can express het-
erologous genes, including HIV envelop, for prolonged
periods of time in cell culture without selection repre-
sents a significant step in developing a new vector system
potentially capable of delivering immunogens to any
host in whose cells the dengue replicons can replicate.
Flavivirus replicons have previously been demonstrated
to express heterologous genes for up to 41 days in tissue
culture in Kunjin [11]. However, these experiments were
done in the presence of selection for the heterologous
genes cloned into the replicons. We have demonstrated
heterologous gene expression in the absence of selection
for up to at least 9 days post transfection with chimeric
dengue replicons. Although we have formally demon-
strated expression, not replication, our previous demon-
stration of the replication [12] of dengue replicons
lacking heterologous material suggests that the replicons
described here, which contain heterologous material, are
indeed replicating. Evidence that cells continue to repli-
cate and express replicon proteins in both daughter cells
after transfection with these chimeric replicons further
supports the implication of chimeric replicon replica-
tion. Ideally, to serve as dual vaccines against dengue as
well as against other pathogens, the replicons should ex-
press the dengue NS1 protein [29–32]. So far, attempts
to visualize NS1 production by Western blots have failed,
presumably because of the low transfection efficiencies.
However, we have previously argued that the replication
of dengue replicons could not take place in the absence of
the essential non-structural gene, NS1, which implies
that NS1 is being made. The frequencies and fluores-
cence intensities of replicon positive cells seen in the ex-
periments reported here are comparable to those seen
for dengue replicons lacking heterologous material [12],
Figure 4
Expression of proteins by ∆ pre-M/E-gp120 48 hours post
transfection. Left and right frames are two independent
fields. Anti-HIV serum was used in these experiments.
Figure 5
Expression of gp160 by ∆ pre-M/E-gp160 48 hours post trans-
fection. Left and right frames are independent fields. Anti-
HIV serum was used in these experiments.BMC Microbiology 2001, 1:28 http://www.biomedcentral.com/1471-2180/1/28
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suggesting that replication of the ∆ pre-M/E replicons
containing heterologous material is occurring as well.
The finding of at least one closely apposed pair of cells
expressing high levels of replicon proteins on day 9 post
transfection, two days after trypsinization and replating
(Figure 7, right panel), not only implies replicon replica-
tion, but also implies the expression of NS-1 protein as
well. The definitive demonstration of effective NS-1 pro-
duction will have to await studies of the immune re-
sponse in animals immunized with these replicons.
Choice of immunogen remains problematic for these
vectors. Clearly, HIV-1 gp160 is too toxic for prolonged
expression. Even the gp120-expressing replicon seems
mildly toxic in that the frequency of gp120 positive cells
declines with time in culture post transfection with ∆ pre-
M/E-gp120 (not shown). However, as noted above, we
have seen at least one instance of putative cellular divi-
sion at least 7 days after being successfully transfected by
∆ pre-M/E-gp120 (Figure 7, right panel). Experiments
are now in progress to determine the feasibility of long
term expression of other HIV-1 immunogens, including
gag and tat.
Conclusion
Demonstration of long term protein expression by a
gp120-expressing replicon alone, of course, does not
demonstrate that the chimeric dengue replicons consti-
tute an effective vaccine. However, at the very least they
add to the potential armamentarium available to the vac-
cinologist. It is highly likely that a successful HIV vacci-
nation protocol will involve multiple immunogens and
delivery protocols. For instance, mice immunized with
attenuated Friend leukemia virus (FLV) develop an im-
mune response whose efficacy is dependent on the addi-
tive effects of at least three separable spleen cell
populations [33]. By analogy, it may be necessary to de-
vise multiple strategies to obtain a similarly complex and
effective immune response in humans against HIV. In
animal models of HIV, different immunogens and modes
of immunization can induce different modes of protec-
tion with varying degrees of effectiveness [34–40] Har-
nessing multiple immune responses may be the answer
to designing an effective HIV vaccine [1] and the availa-
bility of multiple vectors may facilitate the harnessing of
multiple responses.
Much work obviously remains to be done to develop den-
gue replicons as effective vectors for HIV immunogens.
More work needs to be done on determining the ability of
dengue replicons to express other potential immuno-
gens, including HIV-1 gag, tat (reviewed in 41) and env
genes with deleted hypervariable regions [see [42]]. An-
imal studies in our lab are currently being initiated to de-
termine the nature of the immune response such vectors
can induce in mice and these studies will presumably
need to be extended to primates. Finally, effective deliv-
ery systems will need to be devised. Although our suc-
cessful development of a plasmid which can express a
dengue replicon from transfected DNA facilitates deliv-
ery by DNA vaccination [12], the development of packag-
ing cell lines which can package these replicons into
virions would be a major step forward towards a vaccine
which could be conveniently administered in typical clin-
ical situations. Experiments are currently underway in
our laboratory to develop such packaging cell lines.
Materials and methods
Culturing of dengue Virus
Dengue virus strains DEN1/WP and DEN2/NGC, kindly
provided by Dr. Lewis Markoff, [43,44] were passaged in
monkey LLC-MK2 cells at 37°C in a humidified incuba-
tor under 5% CO2, using Medium 199 plus 10% fetal bo-
vine serum (FBS) and 50 ug of Gentamicin per ml. The
cells were trypsinized a day before virus infection and
Figure 6
Expression of gp160 by ∆ pre-M/E-gp160 36 hours post trans-
fection. Anti-dengue Serum was used in these experiments.
Left and right panels are independent fields.
Figure 7
Expression of proteins by ∆ pre-M/E-gp120 9 days post trans-
fection. Cells were trypsinized and replated on day 7 post
transfection and harvested for immunofluorescence two days
later. Left and right frames are two independent fields. Anti-
dengue serum was used in these experiments.BMC Microbiology 2001, 1:28 http://www.biomedcentral.com/1471-2180/1/28
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plated to reach approximately 80% confluence on the
day of infection. Infections were typically at an MOI of
0.01 PFU/cell in Medium 199 plus 2% FBS.
In vitro mutagenesis
Heterologous genes were cloned into the previously de-
scribed ∆ pre-M/E replicon [12], into the position previ-
ously occupied by the pre-M/E genes. DNA fragments
used for desired regions of heterologous genes (see Fig-
ure 1) were synthesized by polymerase chain reaction
(PCR) from short overlapping primers. For the Green
Fluorescent Protein (GFP) gene, the 5' primer was
5'CGAAAAAAGGCGAGAAATACGCCTTTCAATATGCT
GAAACGCGAGAGAATGGTGAGCAAGGGCGAGGAGCT
G3' and the 3' primer was
5'AAGGTCAAAATTCAACAGCTGCTTGTACAGCTCGTC
CATGCC3'. For HIV-1 gp120 gene, the 5' primer was
5'ATCATTATGCTGAATCCAACAGTGATGGCGTTCCAT
TTACCACACGTAACATGAGAGTGATGGGGATCAGGA
AG3' and the 3' primer was
5'AAGGTCAAAATTCAACAGCTGGGTGGGTGCTAATC
CTAATGGTTC3'. GFP and HIV-1 gp120 were fused with
FMDV/2A self cleaving protein sequence to replace nat-
ural cleavage sites in the dengue polyprotein. These sites
seem to loose their activity when juxtaposed with heter-
ologous material (data not shown). PCR was used to am-
plify DNA coding for the FMDV/2A self cleaving protein
The 5' primer was
5'CAGCTGTTGAATTTTGACCTTCTTAAGCTTGCGGGA





Dengue-2 virus cDNA cloned in the yeast shuttle vector
pRS424, linearized by excision of a short Bam H1 frag-
ment was transfected into competent [45] S. cerevisiae
YPH857 (kindly provided by Barry Falgout, (CBER/
FDA), along with the appropriate PCR fragment span-
ning the desired deletion. Yeast colonies which grew on
tryptophan minus plates represented vectors which had
recircularized by homologous recombination with these
PCR fragments [35]. DNA from these colonies was trans-
formed into E. coli STBL 2 cells (Life Technologies, Inc.)
to make sufficient quantities of dengue recombinant, ge-
nomic-length DNAs for characterization and analysis.
Expression of virus & replicons in cells
The full length virus and replicon cDNA plasmids isolat-
ed from STBL 2 cells were linearized with Sac I, purified
by Qiagen chromatography, and eluted by RNAase-free
water in preparation for transcription. The transcription
reaction mixtures contained lug of linearized DNA; 0.5
mM(each) ATP, CTP, and UTP; 0.1 mM GTP; 0.5 mM
cap analog (NEBL); 10 mM DTT; 40 U of Rnasin (Prome-
ga); 30 U of SP6 RNA polymerase; and 1 ×  SP6 RNA
polymerase buffer (Promega) in a volume of 30 ul. The
reaction mixtures were incubated at 400°C for 2 hr. Aliq-
uots (12.5 ul) of the reaction mixtures, containing full
length viral RNA, were used to transfect approximately 2
×  106 Monkey LLC-MK2 cells in phosphate-buffered sa-
line (PBS) by electroporation in a 0.4 cm gap electropo-
ration cuvette. Each cuvette was pulsed at 200 V, 950 uF
using a BioRad Genepuls electroporator. The cells were
then resuspended in growth medium and plated on the
appropriate tissue culture dish.
After electroporation, cells were either plated directly on
multiwell plates for harvest at short time periods (typi-
cally 4 days or less) or on tissue culture dishes for
trypsinization and seeding onto multiwell plates one or
two days before final harvest for longer time periods.
Figure 8
Simultaneous expression of HIV and dengue proteins by
∆ pre-M/E-gp120-transfected cells 4 days post transfection.
Left frame: FITC detection of HIV proteins. Right frame:
Rhodamine detection of dengue proteins.
Figure 9
Simultaneous expression of HIV and dengue proteins by
∆ pre-M/E-gp120-transfected cells 7 days post transfection.
Left frame: FITC detection of HIV proteins. Right frame:
Rhodamine detection of dengue proteins.BMC Microbiology 2001, 1:28 http://www.biomedcentral.com/1471-2180/1/28
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Immuno-histochemical methods
For immunofluorescent detection of dengue-specific
proteins, cells growing on chamber slides were rinsed in
room-temperature PBS and then fixed in cold acetone
for 10 min at -20°C. After being air dried, each chamber
was covered with 50 ul of a 1:50 dilution of DEN2-specif-
ic hyperimmune mouse ascitic fluid (HMAF, American
Type Culture Collection) in PBS plus 2% normal goat se-
rum and incubated at room temperature for 1 h in a hu-
midified atmosphere and then rinsed twice in PBS. After
washing, cells were subsequently incubated with a 1:100
dilution of fluorescein isothiocyanate-labeld goat anti-
mouse antibodies (Kirkegaard and Perry Laboratory)
and rinsed twice in PBS. For detection of HIV-specific
proteins, the same protocol was used except that cells
were initially incubated with human HIV-1 serum from
Waldheim Pharmazeutika Ges.m.b.H. Neufeld-Vienna,
Austria and then subsequently incubated with fluores-
cent-labeled goat anti-human antibody. Cells in some,
but not all experiments were counterstained with 0.02%
Evans Blue.
For dual labeling, the first antibodies were a 1:50 dilution
of dengue type 2 specific hyperimmune mouse ascitic
fluid (HMAF, American type culture collection) and a
1:100 dilution of human HIV positive serum in PBS plus
2% normal goat serum. The second antibodies were a
1:100 dilution of FITC-labeled goat anti-human antibod-
ies (Waldeim Pharmazeutika) and a 1:50 dilution of goat
anti-mouse IgG-L-Rhodamine (Boehringer Mannheim
Biochemicals).
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